A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s) - Join Clinical Trial NCTNCT06799520
How to Join This Clinical Trial - NCTNCT06799520
Learn how to participate in this PHASE1 trial studying an investigational therapy for Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA), Immune-mediated Focal Segmental Glomerulosclerosis (FSGS). This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA), Immune-mediated Focal Segmental Glomerulosclerosis (FSGS). Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA), Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE1 - Early safety study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT06799520 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 6 locations. Find a study site near you:
Clinical Research Site
Sofia, 1404 - Bulgaria
Status: RECRUITING
Clinical Research Site
Chisinau, MD-2025 - Moldova
Status: RECRUITING
Clinical Research Site
Bucharest, 11658 - Romania
Status: RECRUITING
Clinical Research Site
Cluj-Napoca, 40006 - Romania
Status: RECRUITING
Clinical Research Site
Barcelona, 8035 - Spain
Status: NOT_YET_RECRUITING
Clinical Research Site
Granada, 18014 - Spain
Status: NOT_YET_RECRUITING
How to Enroll in This Study
To learn more about participating in this PHASE1 clinical trial for Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA), Immune-mediated Focal Segmental Glomerulosclerosis (FSGS):
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships